Zynerba Press Releases

29 Sep 22 Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference

22 Sep 22 Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

8 Sep 22 Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

6 Sep 22 Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

31 Aug 22 Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

10 Aug 22 Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

3 Aug 22 Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

21 Jul 22 Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

7 Jul 22 Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

22 Jun 22 Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome